Stocks Health care RARE
NASDAQ · Health careUltragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. brought in $730M of revenue over the twelve months to September 30, 2026, up 15.8% from a year earlier. It posted a net loss of $524M. In fiscal 2025 capital spending exceeded operating cash flow by $472M. At September 30, 2026 it held $150M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Ultragenyx Pharmaceutical Inc.
- Net worth
- Ultragenyx Pharmaceutical Inc. has a market value (market cap) of $1.5B at the latest share price, and shareholders' equity of -$376M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $673M (+20.2% year on year), with a net loss of $575M. Over the 12 months to September 30, 2026: revenue $730M, net loss $524M.
- Cash flow
- In fiscal 2025 operations used $466M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Ultragenyx Pharmaceutical Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Ultragenyx Pharmaceutical Inc. does
Ultragenyx Pharmaceutical Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RARE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $673M | -$575M | -$5.83 | -$472M |
| 2024 | $560M | -$569M | -$6.29 | -$421M |
| 2023 | $434M | -$607M | -$8.25 | -$519M |
| 2022 | $363.3M | -$707.4M | -$10.12 | -$496.6M |
| 2021 | $351.4M | -$454M | -$6.70 | -$411.8M |
| 2020 | $271M | -$186.6M | -$3.07 | -$176.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where RARE ranks in Health care
Latest SEC filings
What Ultragenyx Pharmaceutical Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 8.1% to $173M versus the same quarter last year; diluted EPS -$1.16 versus -$1.81.
- November 3, 2026
- October 30, 2026Passive stake changed SCHEDULE 13G/A
- October 20, 2026Passive stake (5% or more) SCHEDULE 13G
- October 19, 2026Other event 8-K
- October 14, 2026
- October 7, 2026Material agreement8-KUltragenyx entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $210 million in cash.
- September 17, 2026Other event 8-K
- September 2, 2026Other event 8-K
- August 19, 2026Other event 8-K
Insider trades
What the people running Ultragenyx Pharmaceutical Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $127.6K worth of shares in the last 90 days and bought none on the open market. 14% of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 15, 2026 | Horn HowardChief Financial Officer | Sold | 7,066 | $107.9K |
| September 15, 2026 | Huizenga Theodore AlanSVP, Chief Accounting Officer | Soldpre-planned (10b5-1) | 1,283 | $17.4K |
| September 3, 2026 | Huizenga Theodore AlanSVP, Chief Accounting Officer | Sold | 161 | $2.3K |
| August 3, 2026 | Horn HowardChief Financial Officer | Soldpre-planned (10b5-1) | 4,696 | $117K |
| August 3, 2026 | Parschauer Karah HerdmanEVP and Chief Legal Officer | Soldpre-planned (10b5-1) | 1,900 | $47.3K |
| July 1, 2026 | Horn HowardChief Financial Officer | Soldpre-planned (10b5-1) | 4,698 | $155.6K |
| June 15, 2026 | Parschauer Karah HerdmanEVP and Chief Legal Officer | Soldpre-planned (10b5-1) | 1,899 | $46.8K |
| June 15, 2026 | Sanders Corazon (Corsee) D.Director | Sold | 2,000 | $50.1K |
Who owns RARE
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| RTW Investments, LP13G, passive with 1 related filers | 7.9% | August 14, 2026 |
| Vanguard Portfolio Management13G, passive | 6.95% | July 31, 2026 |
| AQR Capital Management, LLC13G, passive with 1 related filers | 6.66% | August 13, 2026 |
| Madison Avenue International LP13G, passive with 5 related filers | 6.4% | October 20, 2026 |
| Vanguard Capital Management13G, passive | 5.13% | July 31, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 310 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 10,654,276 | +3,354,678 |
| Rtw Investments, LP | 7,796,895 | +4,148,100 |
| Vanguard Portfolio Management LLC | 6,790,135 | +1,404,143 |
| Aqr Capital Management LLC | 6,560,809 | +1,982,785 |
| State Street Corp | 6,158,766 | +1,137,325 |
| Vanguard Capital Management LLC | 4,296,491 | +106,660 |
| Two Sigma Investments, LP | 3,621,200 | +1,415,380 |
| Sands Capital Management, LLC | 3,158,368 | -56,165 |
| Jacobs Levy Equity Management, Inc | 2,939,719 | +1,508,648 |
| Frontier Capital Management Co LLC | 2,847,936 | +656,754 |
| Geode Capital Management, LLC | 2,578,828 | +729,437 |
| Bellevue Group AG | 1,982,775 | -397,225 |
| D. E. Shaw & Co., Inc. | 1,730,193 | +469,175 |
| Sofinnova Investments, Inc. | 1,717,505 | -1,428,383 |
| Adage Capital Partners GP, L.L.C. | 1,580,000 | +1,100,000 |
| Mpm Bioimpact LLC | 1,418,215 | new |
| Morgan Stanley | 1,324,805 | -175,723 |
| Wellington Management Group Llp | 1,250,464 | -1,390,348 |
| Voloridge Investment Management, LLC | 1,241,556 | -185,278 |
| Bank of America Corp | 1,148,454 | +101,908 |
Insiders
15 insiders reported holding 1,729,285 shares in total, about $26.7M at the last price.
| Holder | Shares |
|---|---|
| Kakkis Emil DPresident & CEO, Director | 735,739 |
| Huang Dennis KarlSee Remarks | 147,845 |
| Pinion John RichardSee Remarks | 133,142 |
| Harris ErikEVP & Chief Commercial Officer | 118,410 |
| Crombez EricEVP and Chief Medical Officer | 111,189 |
| Parschauer Karah HerdmanEVP and Chief Legal Officer | 92,562 |
| Horn HowardChief Financial Officer | 89,229 |
| Huizenga Theodore AlanSVP, Chief Accounting Officer | 67,863 |
| Welch Daniel GDirector | 40,441 |
| Narachi MichaelDirector | 40,441 |
Questions about RARE
What does Ultragenyx Pharmaceutical Inc. do?
Ultragenyx Pharmaceutical Inc. is a company in the Health care sector, listed on NASDAQ as RARE. Its shares trade on NASDAQ under the ticker RARE.
What is Ultragenyx Pharmaceutical Inc.'s net worth?
Ultragenyx Pharmaceutical Inc. has a market value (market cap) of $1.5B at the latest share price, and shareholders' equity of -$376M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Ultragenyx Pharmaceutical Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $524M on revenue of $730M.
How much revenue does Ultragenyx Pharmaceutical Inc. make?
Over the twelve months to September 30, 2026 Ultragenyx Pharmaceutical Inc. reported revenue of $730M. That is 15.8% more than a year earlier.
When did Ultragenyx Pharmaceutical Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026.
When is Ultragenyx Pharmaceutical Inc.'s next earnings report?
Ultragenyx Pharmaceutical Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare RARE with
Follow RARE
Get an email when Ultragenyx Pharmaceutical Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Ultragenyx Pharmaceutical Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.